Sanofi Adr Stock Price To Earnings To Growth

SNY Stock

USD 47.98 0.20 0.42%

Sanofi ADR fundamentals help investors to digest information that contributes to Sanofi ADR's financial success or failures. It also enables traders to predict the movement of Sanofi Stock. The fundamental analysis module provides a way to measure Sanofi ADR's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sanofi ADR stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Sanofi ADR Company Price To Earnings To Growth Analysis

Sanofi ADR's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.

PEG Ratio

PE Ratio

EPS Growth

More About Price To Earnings To Growth | All Equity Analysis

Current Sanofi ADR Price To Earnings To Growth

0.75 X

Most of Sanofi ADR's fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sanofi ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Sanofi Price To Earnings To Growth Driver Correlations

Understanding the fundamental principles of building solid financial models for Sanofi ADR is extremely important. It helps to project a fair market value of Sanofi Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since Sanofi ADR's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sanofi ADR's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sanofi ADR's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Accounts Payable	Net Receivables	Good Will	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Current Deferred Revenue	Retained Earnings	Long Term Debt	Property Plant Equipment	Treasury Stock	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.99	0.66	0.84	0.85	1.0	-0.61	0.98	0.9	0.6	0.79	0.84	0.15	0.02	0.68	0.56	0.01	0.48	0.32	-0.52	-0.02	0.57	0.55	0.43	-0.19	-0.02
Total Stockholder Equity	0.99		0.56	0.84	0.84	0.99	-0.6	0.95	0.9	0.58	0.78	0.84	0.1	0.02	0.63	0.59	-0.02	0.5	0.33	-0.5	0.08	0.52	0.5	0.43	-0.18	-0.01
Net Debt	0.66	0.56		0.56	0.6	0.66	-0.32	0.77	0.47	0.52	0.7	0.48	0.25	-0.11	0.64	0.25	0.25	0.35	0.16	-0.33	-0.65	0.61	0.54	0.38	-0.41	-0.05
Accounts Payable	0.84	0.84	0.56		0.57	0.84	-0.26	0.8	0.77	0.4	0.59	0.46	-0.18	-0.08	0.41	0.28	-0.05	0.69	0.31	-0.65	-0.02	0.75	0.69	0.66	-0.48	0.04
Net Receivables	0.85	0.84	0.6	0.57		0.85	-0.82	0.85	0.7	0.63	0.74	0.89	0.52	0.05	0.68	0.65	-0.03	0.03	0.22	-0.25	-0.08	0.21	0.21	0.09	-0.12	-0.12
Good Will	1.0	0.99	0.66	0.84	0.85		-0.6	0.98	0.9	0.58	0.79	0.83	0.16	0.01	0.7	0.57	-0.03	0.48	0.34	-0.55	-0.04	0.56	0.53	0.42	-0.2	-0.03
Short Term Investments	-0.61	-0.6	-0.32	-0.26	-0.82	-0.6		-0.59	-0.46	-0.29	-0.46	-0.87	-0.72	-0.19	-0.57	-0.65	0.16	0.29	0.18	0.2	0.02	0.09	0.03	0.19	0.15	-0.02
Total Liab	0.98	0.95	0.77	0.8	0.85	0.98	-0.59		0.89	0.6	0.79	0.81	0.21	0.01	0.72	0.51	0.04	0.44	0.31	-0.54	-0.16	0.62	0.59	0.41	-0.2	-0.04
Total Current Assets	0.9	0.9	0.47	0.77	0.7	0.9	-0.46	0.89		0.51	0.52	0.7	0.06	0.17	0.54	0.36	-0.01	0.43	0.44	-0.64	0.16	0.66	0.68	0.39	0.02	-0.04
Short Term Debt	0.6	0.58	0.52	0.4	0.63	0.58	-0.29	0.6	0.51		0.63	0.55	0.07	0.13	0.25	0.27	0.35	0.23	0.25	0.1	-0.09	0.35	0.34	0.35	-0.09	0.07
Intangible Assets	0.79	0.78	0.7	0.59	0.74	0.79	-0.46	0.79	0.52	0.63		0.73	0.04	-0.21	0.56	0.53	0.16	0.49	0.2	-0.13	-0.22	0.35	0.27	0.47	-0.24	0.15
Common Stock	0.84	0.84	0.48	0.46	0.89	0.83	-0.87	0.81	0.7	0.55	0.73		0.43	0.1	0.69	0.74	-0.01	0.08	0.08	-0.29	0.03	0.16	0.18	0.12	-0.06	0.13
Current Deferred Revenue	0.15	0.1	0.25	-0.18	0.52	0.16	-0.72	0.21	0.06	0.07	0.04	0.43		0.26	0.39	0.32	-0.23	-0.71	-0.13	0.1	-0.23	-0.37	-0.3	-0.69	0.05	-0.42
Retained Earnings	0.02	0.02	-0.11	-0.08	0.05	0.01	-0.19	0.01	0.17	0.13	-0.21	0.1	0.26		-0.13	-0.11	0.07	-0.18	0.14	-0.08	0.41	0.04	0.22	-0.24	0.12	-0.11
Long Term Debt	0.68	0.63	0.64	0.41	0.68	0.7	-0.57	0.72	0.54	0.25	0.56	0.69	0.39	-0.13		0.77	0.07	0.16	0.36	-0.5	-0.34	0.24	0.2	0.09	-0.02	-0.13
Property Plant Equipment	0.56	0.59	0.25	0.28	0.65	0.57	-0.65	0.51	0.36	0.27	0.53	0.74	0.32	-0.11	0.77		0.13	0.06	0.16	-0.14	0.1	-0.13	-0.16	-0.04	-0.01	-0.06
Treasury Stock	0.01	-0.02	0.25	-0.05	-0.03	-0.03	0.16	0.04	-0.01	0.35	0.16	-0.01	-0.23	0.07	0.07	0.13		0.26	0.0	0.24	0.0	0.31	0.32	0.24	-0.12	0.11
Deferred Long Term Liab	0.48	0.5	0.35	0.69	0.03	0.48	0.29	0.44	0.43	0.23	0.49	0.08	-0.71	-0.18	0.16	0.06	0.26		0.34	-0.42	0.02	0.73	0.63	0.84	-0.3	0.23
Long Term Investments	0.32	0.33	0.16	0.31	0.22	0.34	0.18	0.31	0.44	0.25	0.2	0.08	-0.13	0.14	0.36	0.16	0.0	0.34		-0.31	0.16	0.25	0.24	0.12	0.4	-0.37
Short Long Term Debt	-0.52	-0.5	-0.33	-0.65	-0.25	-0.55	0.2	-0.54	-0.64	0.1	-0.13	-0.29	0.1	-0.08	-0.5	-0.14	0.24	-0.42	-0.31		0.11	-0.64	-0.66	-0.47	0.25	-0.22
Net Tangible Assets	-0.02	0.08	-0.65	-0.02	-0.08	-0.04	0.02	-0.16	0.16	-0.09	-0.22	0.03	-0.23	0.41	-0.34	0.1	0.0	0.02	0.16	0.11		-0.21	-0.1	-0.16	0.4	-0.09
Long Term Debt Total	0.57	0.52	0.61	0.75	0.21	0.56	0.09	0.62	0.66	0.35	0.35	0.16	-0.37	0.04	0.24	-0.13	0.31	0.73	0.25	-0.64	-0.21		0.98	0.76	-0.39	0.18
Capital Surpluse	0.55	0.5	0.54	0.69	0.21	0.53	0.03	0.59	0.68	0.34	0.27	0.18	-0.3	0.22	0.2	-0.16	0.32	0.63	0.24	-0.66	-0.1	0.98		0.68	-0.35	0.2
Net Invested Capital	0.43	0.43	0.38	0.66	0.09	0.42	0.19	0.41	0.39	0.35	0.47	0.12	-0.69	-0.24	0.09	-0.04	0.24	0.84	0.12	-0.47	-0.16	0.76	0.68		-0.5	0.61
Net Working Capital	-0.19	-0.18	-0.41	-0.48	-0.12	-0.2	0.15	-0.2	0.02	-0.09	-0.24	-0.06	0.05	0.12	-0.02	-0.01	-0.12	-0.3	0.4	0.25	0.4	-0.39	-0.35	-0.5		-0.38
Capital Stock	-0.02	-0.01	-0.05	0.04	-0.12	-0.03	-0.02	-0.04	-0.04	0.07	0.15	0.13	-0.42	-0.11	-0.13	-0.06	0.11	0.23	-0.37	-0.22	-0.09	0.18	0.2	0.61	-0.38

Click cells to compare fundamentals

Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.

Competition

Predict Sanofi ADR

Sanofi Price Earnings To Growth Ratio

Price Earnings To Growth Ratio

(0.56)

At this time, Sanofi ADR's Price Earnings To Growth Ratio is fairly stable compared to the past year.

Based on the latest financial disclosure, Sanofi ADR has a Price To Earnings To Growth of 0.7454 times. This is 4.99% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The price to earnings to growth for all United States stocks is 84.76% higher than that of the company.

Sanofi Price To Earnings To Growth Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sanofi ADR's direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sanofi ADR could also be used in its relative valuation, which is a method of valuing Sanofi ADR by comparing valuation metrics of similar companies.

Sanofi ADR is currently under evaluation in price to earnings to growth category among its peers.

Sanofi ADR ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Sanofi ADR's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Sanofi ADR's managers, analysts, and investors.

Environmental

Governance

Social

Sanofi Fundamentals

	Return On Equity	0.0582
	Return On Asset	0.0416
	Profit Margin	0.09 %
	Operating Margin	0.29 %
	Current Valuation	138.01 B
	Shares Outstanding	2.51 B
	Shares Owned By Institutions	11.64 %
	Number Of Shares Shorted	8.12 M
	Price To Earning	7.78 X
	Price To Book	1.57 X
	Price To Sales	2.49 X
	Revenue	46.03 B
	Gross Profit	31.7 B
	EBITDA	12.6 B
	Net Income	5.4 B
	Cash And Equivalents	6.9 B
	Cash Per Share	2.76 X
	Total Debt	18.42 B
	Debt To Equity	0.30 %
	Current Ratio	1.30 X
	Book Value Per Share	58.10 X
	Cash Flow From Operations	10.26 B
	Short Ratio	4.07 X
	Earnings Per Share	1.90 X
	Price To Earnings To Growth	0.75 X
	Target Price	63.49
	Number Of Employees	86.09 K
	Beta	0.45
	Market Capitalization	120.73 B
	Total Asset	126.46 B
	Retained Earnings	67.5 B
	Working Capital	6.46 B
	Current Asset	24.93 B
	Current Liabilities	16.82 B
	Annual Yield	0.04 %
	Five Year Return	3.85 %
	Net Asset	126.46 B

About Sanofi ADR Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Sanofi ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sanofi ADR using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sanofi ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Sanofi Stock Analysis

When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC